225 related articles for article (PubMed ID: 26260911)
1. Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.
Ni J; Zhu T; Zhao L; Che F; Chen Y; Shou H; Yu A
Clin Transl Oncol; 2015 Oct; 17(10):835-9. PubMed ID: 26260911
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
3. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
Tian WY; Wang YM; Yan Y; Gao JP; Sun DD; Jiang S; Sheng Y; Teng F; Xue FX
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):810-817. PubMed ID: 27916063
[No Abstract] [Full Text] [Related]
4. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
5. [Clinical implications of positive peritoneal cytology in endometrial cancer].
Ren YL; Wang HY; Shan BE; Ping B; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2011 Aug; 46(8):595-9. PubMed ID: 22169518
[TBL] [Abstract][Full Text] [Related]
6. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer.
Robbins JR; Gayar OH; Zaki M; Mahan M; Buekers T; Elshaikh MA
Gynecol Oncol; 2013 Dec; 131(3):593-7. PubMed ID: 24125752
[TBL] [Abstract][Full Text] [Related]
7. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
9. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of solid growth in endometrioid endometrial adenocarcinoma.
Akar S; Çelik ZE; Fındık S; İlhan TT; Ercan F; Çelik Ç
Int J Clin Oncol; 2020 Jan; 25(1):195-202. PubMed ID: 31452018
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in endometrial carcinoma: correlation with survival and clinicopathologic risk factors.
Ozuysal S; Bilgin T; Ozan H; Kara HF; Oztürk H; Ercan I
Gynecol Obstet Invest; 2003; 55(3):173-7. PubMed ID: 12865598
[TBL] [Abstract][Full Text] [Related]
12. Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer.
Chattopadhyay S; Galaal KA; Patel A; Fisher A; Nayar A; Cross P; Naik R
BJOG; 2012 Sep; 119(10):1162-70. PubMed ID: 22804815
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
Scott SA; van der Zanden C; Cai E; McGahan CE; Kwon JS
Gynecol Oncol; 2017 May; 145(2):262-268. PubMed ID: 28359690
[TBL] [Abstract][Full Text] [Related]
14. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.
Steiner E; Eicher O; Sagemüller J; Schmidt M; Pilch H; Tanner B; Hengstler JG; Hofmann M; Knapstein PG
Int J Gynecol Cancer; 2003; 13(2):197-203. PubMed ID: 12657124
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
16. Defining prognostic variables in recurrent endometrioid endometrial cancer: a 15-year single-institution review.
Esselen KM; Boruta DM; del Carmen M; Schorge JO; Goodman A; Growdon WB
Int J Gynecol Cancer; 2011 Aug; 21(6):1078-83. PubMed ID: 21633304
[TBL] [Abstract][Full Text] [Related]
17. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
[TBL] [Abstract][Full Text] [Related]
18. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
Soeda S; Nakamura N; Ozeki T; Nishiyama H; Hojo H; Yamada H; Abe M; Sato A
Gynecol Oncol; 2008 Apr; 109(1):122-8. PubMed ID: 18289648
[TBL] [Abstract][Full Text] [Related]
20. Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis.
Rauh-Hain JA; Vargas RJ; Clemmer J; Clark RM; Bradford LS; Growdon WB; Goodman A; Boruta DM; Schorge JO; del Carmen MG
Am J Clin Oncol; 2016 Feb; 39(1):43-8. PubMed ID: 24390270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
